Thursday, 28 May 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 28 May 2026
News

Drug pulled after viability review

Posted 27 May 2026 PM

Amgen is in the process of pulling Kanjinti, a biosimilar of Roche’s previously withdrawn intravenously delivered targeted monoclonal antibody Herceptin, from the Australian market.

The 150 mg strength of Kanjinti was deleted from the market on 1 January, with the 420 mg strength to be deleted from the market on 30 September. The 60 mg strength, although registered on the ARTG, was never launched in Australia.

To see the whole article, please login

Popular

Gladys takes health sector role
Country Leader back after Gap Year
Dark Horse climbs Innovation Index
Sanofi ends 100-year drought
Latest Jobs
Pharma in Focus  Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home